JPS5910574A - Triazole derivative and its preparation - Google Patents

Triazole derivative and its preparation

Info

Publication number
JPS5910574A
JPS5910574A JP11900982A JP11900982A JPS5910574A JP S5910574 A JPS5910574 A JP S5910574A JP 11900982 A JP11900982 A JP 11900982A JP 11900982 A JP11900982 A JP 11900982A JP S5910574 A JPS5910574 A JP S5910574A
Authority
JP
Japan
Prior art keywords
derivative
formula
salt
group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11900982A
Other languages
Japanese (ja)
Inventor
Hisae Haruta
春田 久恵
Kazushige Kawada
河田 和茂
Kunikazu Takai
高井 国和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to JP11900982A priority Critical patent/JPS5910574A/en
Publication of JPS5910574A publication Critical patent/JPS5910574A/en
Pending legal-status Critical Current

Links

Abstract

NEW MATERIAL:The triazole derivative of formula I (R1 is cycloalkyl or aminoalkyl-substituted aryl; R2 is lower alkoxy, halogen-substituted aryl, or N-containing 6-membered aromatic heterocyclic group) and its salt. EXAMPLE:5-(4-Chlorophenyl)-4-cyclohexyl-2,4-dihydro-3H-1,2,4-triazole- 3-thione. USE:It has excellent antimicrobial activity, and is useful as a fungicide, especially fungicide for phytopathogenic fungi. PROCESS:The compound of formula I can be prepared by reacting the thiosemicarbazide derivative of formula II with the compound of formula III, its salt, or its reactive derivative at the carboxyl group in a solvent such as methanol, and treating the resultant 1-acylthiosemicarbazide derivative of formula IV with a base.

Description

【発明の詳細な説明】 この発明は、一般式 (式中、R1はシクロアルキル基またはアミノアルキル
置換アリール基、R2は低級アルコキシもしくはハロゲ
ンで置換されたアリール基または窒素含有6員芳香複素
環式基をそれぞれ意味する) で示される新規なトリアゾール誘導体およびその塩なら
びにそれらの製造法に関するものである○ 十記一般式(1)においてR1で表わされるシクロアル
キル基としてはシクロプロピル、シクロブチル、シクロ
ペンチル、シクロヘキシル、シクロへブチル等が挙げら
れ、゛アリール基としてはフェニル、ナフチル、トリル
、キシリル、メシチル等が挙げられる。これらのアリー
ル基はアミノアルキル基で置換されており、該アミノア
ルキル基トしては例えばメチルアミノ、ジメチルアミノ
、エチルアミノ、ジエチルアミノ、プロピルアミノ、ジ
プロピルアミノ、イソプロピルアミノ、ジイソプロピル
アミノ、ブチルアミノ、ジプチルアミノ、ペンチルアミ
ノ、シベンチルアミノ、ヘキシルアミノ、ジエチルアミ
ノ等のモノモジくはジアルキルアミノ基が挙げられる。
DETAILED DESCRIPTION OF THE INVENTION This invention is based on the general formula (wherein R1 is a cycloalkyl group or an aminoalkyl-substituted aryl group, and R2 is a lower alkoxy or halogen-substituted aryl group or a nitrogen-containing 6-membered aromatic heterocyclic group). The cycloalkyl group represented by R1 in the general formula (1) includes cyclopropyl, cyclobutyl, cyclopentyl, Examples of the aryl group include cyclohexyl and cycloheptyl, and examples of the aryl group include phenyl, naphthyl, tolyl, xylyl, and mesityl. These aryl groups are substituted with aminoalkyl groups, such as methylamino, dimethylamino, ethylamino, diethylamino, propylamino, dipropylamino, isopropylamino, diisopropylamino, butylamino, Examples include monomodal or dialkylamino groups such as diptylamino, pentylamino, cybentylamino, hexylamino, and diethylamino.

R2で表わされるアリール基としては、1−記のR1で
表わされるアリ−/L/基と同様なものが例示され、こ
れらのアリール基は低級アルコキシ基またはハロゲンで
置換されており、該低級アルコキシ基としてはメトキシ
、エトキシ、プロポキシ、イソプロポキシ、ブトキシ、
ペンチルオキシ、ヘキシル、4キシ等が挙げられ、また
ハロゲンとしては塩素、臭素、ヨウ素、フッ素が挙げら
れる。
Examples of the aryl group represented by R2 include those similar to the ary-/L/ group represented by R1 in 1-, and these aryl groups are substituted with a lower alkoxy group or a halogen, and the lower alkoxy The groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy,
Examples of the halogen include pentyloxy, hexyl, and 4-oxy, and examples of the halogen include chlorine, bromine, iodine, and fluorine.

なお、R1およびR2で表わされるア!J −/L/基
上の置換分の数は1個に限定されず、その置換位置も任
意である。
In addition, A! represented by R1 and R2! The number of substitutions on the J −/L/ group is not limited to one, and the substitution position is also arbitrary.

また、R2で表わされる窒素含有6員芳香複素環式姑と
してはピリジル、ピラジニル、ビリミル シニル、ビリタシニル、ピコリル、槃チジル等が挙げら
れる、 これらの目的化合物(1)の塩としては、酢酸、クエン
酸、酒石酸、メタンスルホン酸等の有機酸もしくは塩酸
、臭化水素酸、硫酸等の無機酸との塩およびナトリウム
塩、カリウム塩、カルシウム塩等の無機塩基との塩、あ
るいはピリジン、トリエチルアミン等の有機塩基との塩
が挙けられる。
Further, examples of the nitrogen-containing 6-membered aromatic heterocyclic ring represented by R2 include pyridyl, pyrazinyl, birimircinyl, bilitacinyl, picolyl, orchidyl, etc. Salts of these target compounds (1) include acetic acid, citric acid, etc. , salts with organic acids such as tartaric acid and methanesulfonic acid or inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid, and salts with inorganic bases such as sodium salts, potassium salts, and calcium salts, or organic acids such as pyridine and triethylamine. Examples include salts with bases.

なお、この発明の目的化合物(laid次の式で示され
るように互変異性体となり得、この発明の目的化合物(
1)には一般式(If)で示される互変異性体をも含む
。しかしながら、この開脚(書では、この発明の目的化
合物を便宜上一般式(1)で表わす。
In addition, the object compound of this invention (laid) can be a tautomer as shown in the following formula, and the object compound of this invention (laid
1) also includes the tautomer represented by the general formula (If). However, in this book, the object compound of the present invention is represented by the general formula (1) for convenience.

(+1         (1) (式中、R1およびR2は前と同じ石味)この発明の目
的化合物(1)は次の反応式で示す方法により製造する
ことができる 1 (式中、R4およびR2は前と同じ意味)上記の反応式
の第1工程で使用される力/Lボン酸(It’)の塩類
としては、ナトリウム塩、カリウムJL1X、カルシウ
ム塩等の無機塩基との塩あるいはピリジン塩、トリエチ
ルアミン塩等の有機塩基との塩が例示され、またカルボ
ン酸ωりのカルボキシ基における反応性誘導体としては
、酸ハライド、酸無水物、活性エステル、活性アミド等
、アシル化反応における通常の反応性誘導体か例示され
る。
(+1 (1) (In the formula, R1 and R2 are the same stone taste as before) The object compound (1) of this invention can be produced by the method shown in the following reaction formula 1 (In the formula, R4 and R2 are (same meaning as before) Salts of the force/L acid (It') used in the first step of the above reaction formula include salts with inorganic bases such as sodium salt, potassium JL1X, calcium salt, or pyridine salts; Salts with organic bases such as triethylamine salts are exemplified, and reactive derivatives at the carboxy group of carboxylic acid ω include acid halides, acid anhydrides, active esters, active amides, etc., which are commonly reactive in acylation reactions. Examples include derivatives.

この反応は通常溶媒中で行われ、溶媒としてはメタノー
ル、エタノール、アセトン、ジオキサン、アセlニトリ
ル、クロロホルム、塩化メチレフ、テトラヒドロフラン
、酢酸エチル、ピリジノ、水等が例示される。反応温度
は特に限定されないが、通常冷却下、室温下ないしは加
温下で反応が行われる。反応生成物(V)は常法により
中離、精製されるが、特に精製することなく、次の第2
」:程に何してもよい。
This reaction is usually carried out in a solvent, and examples of the solvent include methanol, ethanol, acetone, dioxane, acelnitrile, chloroform, methylene chloride, tetrahydrofuran, ethyl acetate, pyridino, and water. Although the reaction temperature is not particularly limited, the reaction is usually carried out under cooling, at room temperature, or under heating. The reaction product (V) is neutralized and purified by a conventional method, but without any particular purification, the reaction product (V) is purified by the following second method.
”: You can do whatever you want.

なお、反応生成物(V)の塩としては、塩酸、臭化水素
酸、硫酸等の無機酸との塩あるいは酢酸、クエン酸、シ
ュウ酸、メタンスルホン酸等の有機酸との塩等が例示さ
れる。
Examples of salts of the reaction product (V) include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid, and salts with organic acids such as acetic acid, citric acid, oxalic acid, and methanesulfonic acid. be done.

第2−■−程の閉環反応で用いられる塩基としては、水
酸化ナトリウム、水酸化カリウム等の水酸化アルカリ金
属、炭酸す1−リウム、炭酸カリウム雪の炭酸アルカリ
金属のような無機塩基、トリエチルアミン、1.8−ン
アザビシクロ(5゜4.0)−7−ウンデセン等の有機
塩基が挙げらこの反応は、通常(例えばメタノール、エ
タノール、イソプロピルアルコール、シオキ→)−7、
テトラヒドロフラン、ジメチルスルホギサイト、水など
の溶1煤中で加熱下に行われる。
The bases used in the ring-closing reaction in step 2-■- include alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, inorganic bases such as alkali metal carbonates such as sodium 1-lium carbonate and potassium carbonate, and triethylamine. This reaction is usually carried out using organic bases such as methanol, ethanol, isopropyl alcohol, siloxane-7,
It is carried out in a solution of tetrahydrofuran, dimethylsulfogysite, water, etc. under heating.

上記の方法で得られる目的化合物(+)は、′1名法に
より単則、精製され、所望により前記のような塩に変換
される。
The target compound (+) obtained by the above method is purified in a simple manner by the 1 name method and, if desired, converted into a salt as described above.

この発明の目的化合物1(1)およびその塩は優れた殺
菌作用を示し、殺菌剤として特に植物病原菌用殺菌剤と
して有用である。
Compound 1 (1) and its salt, the object of this invention, exhibit excellent bactericidal activity and are useful as bactericidal agents, particularly as bactericidal agents for plant pathogens.

この発明の目的化合物(Hのうち、例えば2,4−ジヒ
ドロ−4−(4−N、N−ジメチルアミノフェニル’)
−5−(3,4,5−)リメトキシフェニル)−3H−
1,2,4−トリアゾール−5−tオンはサブロー寒天
培地上抗菌試験(60°C)において、フザリウム・ロ
ーセム(Fusarium rO8enl)野外分離菌
株に対して3.13 try/ml、リゾク1−ニア(
Rhizoctonia )属の野外分離菌株に苅して
0、78 ti9’/ml 、 y、りvo−y−=y
 < 5clerotinia)属の野外分離菌株に対
して6.25 p7/m/の最少生育1利II−濃度を
示した。
The object compound of this invention (among H, for example, 2,4-dihydro-4-(4-N,N-dimethylaminophenyl')
-5-(3,4,5-)rimethoxyphenyl)-3H-
1,2,4-triazole-5-t-one was found to be 3.13 tries/ml against field isolates of Fusarium rO8enl in an antibacterial test on Sabouraud agar (60°C), (
0.78 ti9'/ml, y, rivo-y-=y
It showed a minimum growth concentration of 6.25 p7/m/for field isolates of the genus Clerotinia.

この発明の目的化合物(1)およびその塩は、単独でも
しくけ他の賦形剤、希釈剤などの添加剤とともに製剤化
して使用される。
The object compound (1) of the present invention and its salts may be used alone or in combination with other excipients, diluents, and other additives.

次にこの発明を実施例により説明する。Next, the present invention will be explained with reference to examples.

実施例1 (1)  4〜シクロヘキシルチオセミカルバジド(8
,1)をビ’)シ:y(70ml)に浴解し、水冷、攬
、押下に4−クロロベンゾイルクロリド(9,3g)の
クロロホルム(100肩l)溶液を滴下する。滴下終了
後室温で2時間攪拌する。反応液に水を加え、これを減
圧下に濃縮して得られる析出物を枦取し、水洗する。こ
れをエタノール(50m/)に−4−シクロへキシルチ
オセミカルバジド−(12,31)を得る。mp215
〜217℃ TR(ヌショール):3430.3370.5310,
1675゜1600.1540.1480,1230.
1140cmN即(DMSαイ16.δ) : 0.6
0〜2.20(10H,m)、4.12(IH,7fi
−F)、7.52(28,d、J=8Hz)、7.68
(1)T、d) 、7.92(2’E(、d、J=8H
z)、9.14(IH。
Example 1 (1) 4-cyclohexylthiosemicarbazide (8
. After completion of the dropwise addition, the mixture was stirred at room temperature for 2 hours. Water is added to the reaction solution, which is concentrated under reduced pressure, and the resulting precipitate is collected and washed with water. This was dissolved in ethanol (50 m/) to obtain -4-cyclohexylthiosemicarbazide (12,31). mp215
~217℃ TR (Nushor): 3430.3370.5310,
1675°1600.1540.1480,1230.
1140cmN (DMS α i 16.δ): 0.6
0-2.20 (10H, m), 4.12 (IH, 7fi
-F), 7.52 (28, d, J=8Hz), 7.68
(1)T, d), 7.92(2'E(, d, J=8H
z), 9.14 (IH.

s)、10.28(IH,5) (2)1−(4−クロロベンゾイル)−4−シクロへキ
シルチオセミカルバジド(61g)を4%、水1’i=
′f化−7−1リウム水lνt(イス(10誹f)と7
(1ムノール(15ml ) !□ □iJ@j’HQ
に加え、8時間加季、1(j7.ff流すZ・。
s), 10.28 (IH, 5) (2) 1-(4-chlorobenzoyl)-4-cyclohexylthiosemicarbazide (61 g) at 4%, water 1'i=
'F-7-1 Lium water lνt (Isu (10 liters) and 7
(1 mnol (15ml) !□ □iJ@j'HQ
In addition, 8 hours addition, 1 (j7.ff flowing Z.

J又11Q’、i後を5U′J−1焦酸でpH6に調整
し、fiト(r、 工4−ルで抽出する。抽出液を水洗
し、硫酸マグネシウムで乾t・’taする。溶媒を留去
し、IA、j隋(24g)をシリカゲルカラムクロマト
クラフィーに(il、、ヘノセンと酢酸エチル(30:
1)の混合溶媒で溶出する。目的物を含む溶出液をμり
圧1に117)K((’tするト、+−t 色粉末状の
5−(4−クロロフェニル)−4−シクロへキシル−2
,4−ジヒドロ−3H−1゜2.4−トリアゾール−6
−チオン(1,51を得る。mp185’に。
Adjust the pH to 6 with 5U'J-1 pyroic acid and extract with filtrate.The extract is washed with water and dried over magnesium sulfate. The solvent was distilled off, and IA, J Sui (24 g) was subjected to silica gel column chromatography (il, henocene and ethyl acetate (30:
Elute with the mixed solvent of 1). The eluate containing the target compound was micronized to a pressure of 1.
,4-dihydro-3H-1゜2.4-triazole-6
-thione (1,51 is obtained.mp185'.

1、R(ヌジョール):3100,2750.1610
.1555゜1505 、1480 、1450 、1
420 、1370 、1290 。
1, R (Nujol): 3100, 2750.1610
.. 1555°1505, 1480, 1450, 1
420, 1370, 1290.

11[10crn Nl\4]t (D’MSO−(16,δ):0.70
〜2.40(IOH,m)、4.26計算値: C,5
7,23,H5,49,N、14.30.S、10.9
1実験値: C,57,61、H,5,51、N、13
.98.S、11.13実施例2 (1)  4−シクロへキシルチオセミカルバシI’ 
(9,2g)をピリジン(70*t)に溶解し、水冷、
閏゛拌丁に6−クロロベンツ゛イルクロリド−(93g
)を浦iTする。’il:’、:干終了後、巨h′品に
てさらに55時[川1゛・□打し次いで室1jAで−P
i、放置する。
11[10crn Nl\4]t (D'MSO-(16, δ): 0.70
~2.40 (IOH, m), 4.26 calculated value: C,5
7, 23, H5, 49, N, 14.30. S, 10.9
1 Experimental value: C, 57, 61, H, 5, 51, N, 13
.. 98. S, 11.13 Example 2 (1) 4-Cyclohexylthiosemicarbashi I'
(9.2g) was dissolved in pyridine (70*t), cooled with water,
6-chlorobenzyl chloride (93 g
). 'il:',: After the drying, another 55 o'clock in the huge h' item [Kawa 1゛・□, then -P in the room 1jA
i.Leave it alone.

反応液に水を加え、Hh幻玉丁にlt珪・3して書られ
る4)1出物)を戸数し、水洗する。これをエタノール
に加球、彎′濡で桿1゛拌したあと、1角取すると、白
の粉末状の1−(3−クロロベンゾイル)−4−シクロ
へキシルチオセミカルバジド(9,64) をrする。
Add water to the reaction solution, add 4) 1), which is written as lt 窪・3 to Hh phantom ball, and wash with water. When this was added to ethanol and stirred for 1 hour with a wet spoon, one cube was taken, and 1-(3-chlorobenzoyl)-4-cyclohexylthiosemicarbazide (9,64) was obtained as a white powder. r.

1丁で(ヌシぢ−ル):3400餐200.3150.
1700゜1680.1600,157[J、1540
.1510.1470゜1300.126[1,123
5,114[)(JNMR(DMSO−d6 、δ):
0.60〜2.10(10H,m)、4.14(IH,
7−o−ド) 、 7.46〜7.96 (5I(、m
) 、 9.22 (I H。
1 piece (Nushiru): 3400 meals 200.3150.
1700°1680.1600,157 [J, 1540
.. 1510.1470°1300.126[1,123
5,114 [) (JNMR (DMSO-d6, δ):
0.60-2.10 (10H, m), 4.14 (IH,
7-o-de), 7.46-7.96 (5I(, m
), 9.22 (IH.

S)、10.40(IH,8) (2)1−(3−クロロベンゾイル)−4−シクロへキ
シルチオセミカルバジド(2,!M)を4%水酸化ナト
リウム氷18液(26,5肩f)とプロパツール(12
*/)の混液に加えて、11時lid加熱還流する。J
之1.右賽fりを10%」暫酸でpH5に調整し、西1
酸エチルで抽出する抽出液を水19.−し、硫酸マグネ
シラl、で乾tA・1する。溶媒を留去し、列渣をシリ
カゲルカラムクロマトクラフィーに(−ILベンゼンと
醋酸エチル(30:1)の混合溶媒でl確111.する
、。
S), 10.40 (IH, 8) (2) 1-(3-chlorobenzoyl)-4-cyclohexylthiosemicarbazide (2,!M) was dissolved in 18 4% sodium hydroxide ice solution (26,5 shoulder f) and property tools (12
*/) and heated to reflux at 11 o'clock. J
No. 1. Adjust the pH to 5 with 10% temporary acid, and add 10%
19. The extract extracted with ethyl acid is mixed with water. - and dry with magnesilate sulfate for 1 tA. The solvent was distilled off, and the residue was subjected to silica gel column chromatography (-IL) using a mixed solvent of benzene and ethyl acetate (30:1).

目的物を角む溶出Z′1芝を凝圧丁に7)−廉11する
と、白色11T末1チ、−の5−(3−クロロフェニル
)−4−シクロl\A°−シルー2.4−ジヒドロ、−
3H−1,2,4−1−リアゾール−3−チオン(1,
0g)を畏る。rrl 7)180〜183C6 ■1頁ヌショール):3100,2750.1610,
1580,1560゜1500.1470,1425,
1370.1290,1100cmNIvlR(EJS
O−16、δ):0.67〜233(10H,m) 、
4.27(IH,)b−1−゛)、7.50〜7.70
.(4H,m)、14.90(1H9)b−ド) 実jiI′l+1例5 (1)  4−シクロへキシルチオセミカルバジド(8
7g)をピリジン(80*t)に溶解し、水冷、撹拌下
ニコチン酸クロリド塩酸塩(10,7g)を少量ずつ加
える。添加終了後、室温で一夜放1r1゛する。反応液
に水を加え、諏圧−トに1農縮して徂ら牙する析出物J
を戸取し、水洗して用ル1jの1−ニコチノイル−4−
シクロへキシルチオセミカルバジド(13,7g)を得
る。これをエタノールから阿結晶すると、氷晶の淡黄褐
色結晶を得る。mp193〜195t;。
When the elution Z'1 that squares the target object is pressed with a coagulation knife 7) - 11, a white 11T powder of 1, - of 5-(3-chlorophenyl)-4-cyclol\A°-silyl 2.4 -dihydro,-
3H-1,2,4-1-riazole-3-thione (1,
0g). rrl 7) 180-183C6 ■1 page Nushor): 3100, 2750.1610,
1580, 1560° 1500.1470, 1425,
1370.1290,1100cmNIvlR(EJS
O-16, δ): 0.67 to 233 (10H, m),
4.27 (IH,)b-1-゛), 7.50-7.70
.. (4H,m), 14.90(1H9)b-do) Real jiI'l+1 Example 5 (1) 4-Cyclohexylthiosemicarbazide (8
7g) was dissolved in pyridine (80*t), and nicotinic acid chloride hydrochloride (10.7g) was added little by little while cooling with water and stirring. After the addition is complete, leave it at room temperature overnight. Add water to the reaction solution and reduce the pressure by 1 hour to form a precipitate.
Take it out, wash it with water, and use it as 1-nicotinoyl-4-
Cyclohexylthiosemicarbazide (13.7 g) is obtained. When this is crystallized from ethanol, light yellow-brown ice crystals are obtained. mp193-195t;.

]、F?(ヌジぢ−ル):3350.3200,310
0,1710゜1700.1600,1550.151
0,1470.1420゜1270.1260.113
0.1030cm103O(DMSO−(16、δ) 
:0.60〜2.20(10H,m) 。
], F? (nujiru): 3350.3200,310
0,1710°1700.1600,1550.151
0,1470.1420°1270.1260.113
0.1030cm103O(DMSO-(16,δ)
:0.60-2.20 (10H, m).

4.14(IH,ブロード)、7.48〜7.60(I
H,m)、7.78(IH,(1)、8.20〜8.3
2(IH,■+)、8.72〜876(IH,m)、9
.08(1B、s) 、9.24(IH,s) 、10
.48(I F(、S ) (2)  1−ニコチノイル−4−シクロへキシルチオ
セミカルバジド(3,3F)を、4%水酸化ナトリウム
水m液(40ml )とプロパツール(18*t)の1
Mr&に加え、8時1ハ1加熱顯流する。
4.14 (IH, Broad), 7.48-7.60 (I
H, m), 7.78 (IH, (1), 8.20-8.3
2 (IH, ■+), 8.72-876 (IH, m), 9
.. 08 (1B, s), 9.24 (IH, s), 10
.. 48 (IF(,S) (2) 1-Nicotinoyl-4-cyclohexylthiosemicarbazide (3,3F) was mixed with 4% sodium hydroxide aqueous solution (40 ml) and propatool (18*t).
In addition to Mr &, 8 o'clock 1 ha 1 heating flow.

反応a(をハjljJ晶酸でpH6に言周事tし、自1
−酸エチルで抽出する。抽出腋を水洗し、G・11゛酸
マグネシウムで乾(!1・”1する。m媒を留去し、姉
F&をシリカゲルカラムクし17トクラフイーにイ寸し
、ベンセンと西トiつ?エチル(7:1)の混合溶θM
で溶出する。目的物を含む、?i出alを岐11−十に
M席;すると、知白色粉末状(7)5−(3−ピリジル
)−4−シクロヘキシ/L=−2,4−ジヒドロ−IH
−1,2,4−)リアゾール6−チオン(08g)を得
る。mp227〜250 t;。
Reaction a was adjusted to pH 6 with crystalline acid, and then
-Extract with ethyl acid. Wash the extracted armpit with water and dry with magnesium G.11. Mixed solution θM of ethyl (7:1)
Elutes with Including the object? 11-10 M position; Then, white powder (7) 5-(3-pyridyl)-4-cyclohexy/L=-2,4-dihydro-IH
-1,2,4-)riazole 6-thione (08 g) is obtained. mp227-250t;.

丁R(ヌシロール):330D、3100,3050,
2740゜1610.1555,1520,1470,
1410,1380゜1290.1265,1190,
1100.1030cm103O,I< (DMSO−
d6  、δ):0.60〜2.30(IOH,m) 
、4.288.12(IH,m) 、8.76〜8.8
4(2)(、m) 、14,001.y’ロード) 実施例4 (1)  4−(4−NUN−ジメチルアミノフェニル
)チオ士ミカルバシド(8,4(1)ヲヒリシン(60
r/)に溶解し、水冷攪拌下、3.4.5− )リット
イージベンゾイルクロリド 1r:、2g)を少−ずつ
加える。添加終了後、氷ンθ丁に65時間、室2昔で6
時間醍拌する。反帛γ(lに水を加メ、減圧ニア′PL
y縮してtIFら11る4、ri’出物をp取し、水、
熱エタノールで順次洗4+、、r、淡褐色粉末状の1−
(3,4,5−トリノ?・六シ ンゾイ/L/)−4−
(4−、、N 、N−ジメチルアミノフェニル)チオセ
ミカルバジド(1’5.6g)を?艮:る。1〕)丁1
185〜187N;。
Ding R (Nushirol): 330D, 3100, 3050,
2740°1610.1555,1520,1470,
1410, 1380° 1290.1265, 1190,
1100.1030cm103O,I< (DMSO-
d6, δ): 0.60 to 2.30 (IOH, m)
, 4.288.12 (IH, m) , 8.76-8.8
4(2)(,m), 14,001. y'load) Example 4 (1) 4-(4-NUN-dimethylaminophenyl)thiomicarbaside (8,4(1)wohiricin (60
3.4.5-) Lit-dibenzoyl chloride 1r:, 2g) was added little by little under water-cooling and stirring. After the addition is complete, put the ice in the oven for 65 hours, then put it in the room for 6 hours.
Time is in full swing. Add water to reaction force γ (l, reduce pressure near 'PL
4, remove the ri' product, water,
Washed sequentially with hot ethanol 4+, r, light brown powder 1-
(3,4,5-Torino?・Rokushinzoi/L/)-4-
(4-,,N,N-dimethylaminophenyl)thiosemicarbazide (1'5.6g)? Ai: Ru. 1) Ding 1
185-187N;.

■ニーfン“シーール):3300,3150,168
0,1635゜1620.1590,1520.14.
60,1340,1210゜1130cIn NMR(DMSO−46、δ):2.88(6H,s)
、3.72(3H,s>。
■Knee “Seal”: 3300, 3150, 168
0,1635°1620.1590,1520.14.
60,1340,1210°1130cIn NMR (DMSO-46, δ): 2.88 (6H, s)
, 3.72 (3H,s>.

3.84(6H,S)、6.68(2H,d、J =8
Hz)、7.20(2H,d、2=8Hz) 、7.3
2(2H,S)、9.44(IH。
3.84 (6H, S), 6.68 (2H, d, J = 8
Hz), 7.20 (2H, d, 2=8Hz), 7.3
2 (2H, S), 9.44 (IH.

7′0−ド S)、9.56(IH,)’0−1’ S
)、1040(IH。
7'0-de S), 9.56(IH,)'0-1' S
), 1040 (IH.

)V−ド 5) (2)  1−(3,4,5−トリメトキシベンゾ、イ
゛ル)−4−(4−N 、 N−ジノデルアミ/フェニ
ル)チオセミカルバジド(2,4g)を4%水酔什ナト
リウ1、水n:f(νと(20*/)プロパツール(9
πt)の混液に力1け−、3114τ間加熱)革流する
。Jy、応でfiをに″塩酸てト・)15とし2、析出
’J5rlを戸数し、水、熱エタノールで1町次fA:
節して促出色結晶性粉末の5−(3゜4.5−トリメト
キシフェニル)−4−(4−、、、、l−J 。
) V-do 5) (2) 4% of 1-(3,4,5-trimethoxybenzo,yl)-4-(4-N,N-dinoderami/phenyl)thiosemicarbazide (2.4 g) Water drunk natriu 1, water n: f (ν and (20 * /) property tool (9
Apply 1 force to the mixture of πt) and heat for 3114τ). Add 15% hydrochloric acid to 15% of the precipitate, add 15% of the precipitate, add 1% of water and hot ethanol:
5-(3゜4.5-trimethoxyphenyl)-4-(4-, , , l-J), a crystalline powder with a sharp color.

14−  ン′メチルアミノフェニル −3H−、1,2.4− トリアシーz+/−3−チオ
ン(19y)をれ)る。llI T:+ 2 7 5〜
2 7 8 ”G。
14-ene'methylaminophenyl-3H-, 1,2,4-triacyanz+/-3-thione (19y). llIT: + 2 7 5~
2 7 8 ”G.

TR(ヌショーバ):3100,2750,1615,
1600,1530。
TR (Nushoba): 3100, 2750, 1615,
1600, 1530.

1520、1470,1420,1345,1260.
1250。
1520, 1470, 1420, 1345, 1260.
1250.

1135、1010cm 1j1・、ii7 ( f−咄so−cE. 6 、δ
):2.92(6H,s)、356(611。
1135, 1010cm 1j1・, ii7 (f-咄so-cE.6, δ
): 2.92 (6H, s), 356 (611.

!”)、3.64(3)(、F:)、6.64(2H,
S)、6.78(2H。
! ”), 3.64 (3) (, F:), 6.64 (2H,
S), 6.78 (2H.

d,J=9Hz)、7.1 2(2H,d,J=9Hz
)、1 394(1H.フロート S)
d, J = 9Hz), 7.1 2 (2H, d, J = 9Hz
), 1 394 (1H. Float S)

Claims (1)

【特許請求の範囲】 1一般式 (式中、It+ ハシクロアルキル基まだはアミノアル
キル置換アリール基、R2は低級アルコキシもしくはハ
ロゲンで置換されたアリール基または窒素含有6@芳香
複素環式基をそれぞれ意味する) で示されるトリアゾール誘導体およびその塩。 2、− 般式 %式% (式中、R1はシクロアルキル基またはアミノアルキル
置換アリール基を意味する) で示されるチオセミカルバジド誘導体に、一般R2C0
0H (式中、R2は低級アルコキシもしくはハロゲ/で置換
されたアリール基または窒素含有6員芳香複素環式基を
意味する) で示される化合物、その塩またはそのカルボギシ基にお
ける反応性誘導体を作用させて、−・般式 (式中、R1およびR2は前と同じ意味)で示される1
−アシルチオセミカルバジド誘導体またはその塩を得、
次いでこれを塩基で処理して、一般式 (式中、R1およびR2は前と同じ、@、味)で示され
るトリアシー/I/誘導体またはその塩を得ることを特
徴とするトリアゾール誘導体の製造法。
[Scope of Claims] 1 General formula (wherein It+ is a cycloalkyl group or an aminoalkyl-substituted aryl group, R2 is a lower alkoxy or halogen-substituted aryl group, or a nitrogen-containing 6@aromatic heterocyclic group, respectively) triazole derivatives and salts thereof. 2, - A thiosemicarbazide derivative represented by the general formula % (wherein R1 means a cycloalkyl group or an aminoalkyl-substituted aryl group), the general R2C0
0H (wherein R2 means an aryl group or a nitrogen-containing 6-membered aromatic heterocyclic group substituted with lower alkoxy or halogen), a salt thereof, or a reactive derivative thereof with a carboxylic group. 1 represented by the general formula (wherein R1 and R2 have the same meanings as before)
- Obtaining an acylthiosemicarbazide derivative or a salt thereof,
A process for producing a triazole derivative, which is then treated with a base to obtain a triacy/I/derivative or a salt thereof represented by the general formula (wherein R1 and R2 are the same as before, @, taste) .
JP11900982A 1982-07-07 1982-07-07 Triazole derivative and its preparation Pending JPS5910574A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11900982A JPS5910574A (en) 1982-07-07 1982-07-07 Triazole derivative and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11900982A JPS5910574A (en) 1982-07-07 1982-07-07 Triazole derivative and its preparation

Publications (1)

Publication Number Publication Date
JPS5910574A true JPS5910574A (en) 1984-01-20

Family

ID=14750728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11900982A Pending JPS5910574A (en) 1982-07-07 1982-07-07 Triazole derivative and its preparation

Country Status (1)

Country Link
JP (1) JPS5910574A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662813B2 (en) 2005-08-18 2010-02-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US7825148B2 (en) 2004-11-18 2010-11-02 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US8053456B2 (en) 2006-05-25 2011-11-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US8183384B2 (en) 2006-05-25 2012-05-22 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US10500193B2 (en) 2011-11-02 2019-12-10 Synta Pharmaceuticals Corporation Combination therapy of HSP90 inhibitors with platinum-containing agents

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362055B2 (en) 2004-11-18 2013-01-29 Synta Pharmaceuticals, Inc. Triazole compounds that modulate HSP90 activity
US7825148B2 (en) 2004-11-18 2010-11-02 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US9090569B2 (en) 2004-11-18 2015-07-28 Synta Pharmaceuticals Corp. Triazone compounds that modulate HSP90 activity
US8901308B2 (en) 2004-11-18 2014-12-02 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
AU2006338265B2 (en) * 2005-08-18 2011-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US7662813B2 (en) 2005-08-18 2010-02-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8183384B2 (en) 2006-05-25 2012-05-22 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8415377B2 (en) 2006-05-25 2013-04-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8835464B2 (en) 2006-05-25 2014-09-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8927548B2 (en) 2006-05-25 2015-01-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US9006277B2 (en) 2006-05-25 2015-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8053456B2 (en) 2006-05-25 2011-11-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US9206162B2 (en) 2006-05-25 2015-12-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US10500193B2 (en) 2011-11-02 2019-12-10 Synta Pharmaceuticals Corporation Combination therapy of HSP90 inhibitors with platinum-containing agents
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors

Similar Documents

Publication Publication Date Title
ES2229809T3 (en) SUBSTITUTED PIRAZOLS USEFUL AS INHIBITORS OF P38 QUINASA.
HU230124B1 (en) Substituted dihydro 3-halo-1h-pyrazole-5-carboxylates their preparation and use
FR2499990A1 (en) PROCESS FOR THE PREPARATION OF QUINOLEINECARBOXYLIC ACID DERIVATIVES, NOVEL PRODUCTS THUS OBTAINED AND THEIR USE AS ANTIBACTERIAL AGENTS
JPS5910574A (en) Triazole derivative and its preparation
WO2007060408A2 (en) L-phenylalanine derivatives and their use as integrin antagonists
JP2520549B2 (en) Fluorocyclopropyl amino acrylate derivative
JPH0778065B2 (en) (6,7-Substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid-O ▲ above 3 ▼, O ▲ above 4) bis (acyloxy-O) Boron compound, salt thereof, and method for producing the same
JP2570686B2 (en) Pyrazole derivatives
DK154763B (en) PROCEDURE FOR THE PREPARATION OF NORFLOXACIN
JPS61263959A (en) 1-aryl-4-quinolone-3-carboxylic acid
Klokol et al. Aliphatic aldehydes in the synthesis of condensed 4-alkyl (cycloalkyl)-2-amino-3-cyano-4H-pyrans
CN104370839A (en) Oxygen ether-4-substituted bitriazole compound as well as preparation method and application of oxygen ether-4-substituted bitriazole compound
CS183491A3 (en) Process for preparing dialkylpyridine-2,3-dicarboxylates and derivatives thereof
JPS5826885A (en) 6-(5-(omega-(1-imidazolyl)-alkyl)-thien-2-yl)- 3-oxo-2,3,4,5-tetrahydro-pyridazine compound
JPS6191183A (en) Quinolonecarboxylic acid derivative
JPS61152682A (en) Pyridonecarboxylic acid derivative, its ester and salt
JPH05125079A (en) Pyrazolo(1,5-a)pyrimidine derivative
DE3814057A1 (en) 6-OXO-PYRIDAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US2719161A (en) Pyridine thiosemicarbazone
CZ19693A3 (en) N-cyanopyridazinone derivatives, process for preparing thereof and herbicidal agents in which said derivatives are comprised
CA1246568A (en) Substituted 6-aryl-1,2,4-triazolo[4,3- b]pyridazines - their preparation and their use
JPS5821916B2 (en) triazolobenzothiazole
Dumitrascu et al. New pyrazoles by 1, 3-dipolar cycloaddition reactions between sydnones and activated alkynes
JPS63310891A (en) Condensed pyridazine compound
JPS5810583A (en) Manufacture of 5,6,7,7a-tetrahydro-4h- thieno(3,2-c)-pyridin-2-one derivative